Advertisement
U.S. markets closed

IO Biotech, Inc. (IOBT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.7600+0.1600 (+10.00%)
At close: 04:00PM EST
1.7500 -0.01 (-0.57%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close1.6000
Open1.6250
Bid1.7100 x 1000
Ask1.8400 x 1200
Day's Range1.6250 - 1.8500
52 Week Range0.8160 - 2.6800
Volume483,755
Avg. Volume156,518
Market Cap115.95M
Beta (5Y Monthly)0.51
PE Ratio (TTM)N/A
EPS (TTM)-2.3600
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IOBT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • IO Biotech, Inc.
    Daily – Vickers Top Buyers & Sellers for 11/16/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • GlobeNewswire

    IO Biotech to Present at 44th Annual Cowen Health Care Conference

    NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that Mai-Britt Zocca, Ph.D., the company’s President and CEO, will be presenting, and both Dr. Zocca and Amy Sullivan, the company’s CFO, will be participating in one-on-one investor meetings at the 44th Annual Cowen Health Care Conference to be held March 4-6, 2024 in Boston

  • Simply Wall St.

    IO Biotech, Inc. (NASDAQ:IOBT) most popular amongst private equity firms who own 61% of the shares, institutions hold 24%

    Key Insights IO Biotech's significant private equity firms ownership suggests that the key decisions are influenced by...

  • GlobeNewswire

    IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

    NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating therapeutic cancer vaccines based on its T-win® platform, announced today that the first patient has been dosed in its Phase 2 trial (NCT05280314) studying treatment with IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in neoadjuvant and adjuvant patients with resectable melanoma or squamous cell carcinoma of the